Genfit Buys Versantis to Rebuild its Liver Disease Portfolio

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 9 (Table of Contents)

Published: 21 Sep-2022

DOI: 10.3833/pdr.v2022.i9.2723     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a bid to bolster its portfolio of liver disease drugs, Genfit has entered into an agreement to acquire Versantis for up to CHF 105 M (US$108...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details